Sarcopenia Treatment Market Growth Report | Size, Share & Scope 2030
[Research Report] The sarcopenia treatment market size is projected to grow from US$ 3,397.62 million in 2022 to US$ 5,264.76 million by 2030; the market is estimated to record a CAGR of 5.6% during 2022–2030.
Market Insights and Analyst View:
An upsurge in the geriatric population and a rise in malnutrition and vitamin deficiency among adults are the key factors driving the market growth. However, the unavailability of direct interventions hampers the sarcopenia treatment market progress. Malnutrition is one of the major risk factors for sarcopenia. According to the World Health Organization (WHO), approximately 2.3 billion adults worldwide were undernourished as of 2021, representing nearly 30% of the global population. Among the reported risk factors, protein-energy deficiency is a frequent cause of sarcopenia. Further, vitamin D deficiency or insufficiency is positively associated with an increased risk of multiple illnesses, such as cancer, obesity, cardiovascular disease, and sarcopenia. According to the National Institutes of Health (NIH), nearly 50% of the world's population suffers from vitamin D insufficiency, and ~1 billion people are vitamin D deficient. In the US, over 35% of adult individuals have vitamin D deficiency.
Growth Drivers:
The geriatric population is prone to sarcopenia, orthopedic disorders, metabolic disorders, and neurological disorders, among others. Sarcopenia is a geriatric condition caused by a progressive loss of the mass and strength of skeletal muscles. It is associated with a higher risk of unfavorable health outcomes, e.g., falls, disabilities, institutionalization, poor quality of life, and mortality. The elderly populace is rising rapidly in developed countries. According to the World Health Organization (WHO), the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. According to the National Library of Medicine, China's elderly population is expanding at one of the quickest rates in the world. By 2040, 28% of China's population is expected to be over 60 years of age. As per national figures of Japan, 29.1% of the 125 million people living in the country are aged 65 or older. According to the 2020 Census, the US population aged 65 and above increased about five times faster than the total population during 1920–2020. In 2020, the number of older population reached 55.8 million, or 16.8% of the total population of the US.
Aging results in a reduction in muscle mass as one of the major changes in body composition. A significant decline in food consumption among elderly people is one of the key factors causing the loss of muscle mass. According to the National Library of Medicine, people from the age group of 50–60 lose nearly 1.5% of muscle strength every year, while 1–2% of muscle mass is lost annually after the age of 60. Compared to general populations, elderly patients have a higher prevalence of sarcopenia. According to an article published in June 2023 in Elsevier, the prevalence of sarcopenia ranges from 18% in diabetic patients to 66% in those with incurable esophageal cancer. Hence, the rising elderly population contributes significantly to the sarcopenia treatment market growth.
There is not a single approved drug that can be prescribed for treating sarcopenia directly. This can also be attributed to the fact that initially promising avenues could not be supported by any consolidated findings of well-conducted randomized controlled trials. Thus, the unavailability of treatment options directly targeting sarcopenia hinders the sarcopenia treatment market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Sarcopenia Treatment Market: Strategic Insights
Market Size Value in US$ 3,397.62 million in 2022 Market Size Value by US$ 5,264.76 million by 2030 Growth rate CAGR of 5.6% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Sarcopenia Treatment Market: Strategic Insights
| Market Size Value in | US$ 3,397.62 million in 2022 |
| Market Size Value by | US$ 5,264.76 million by 2030 |
| Growth rate | CAGR of 5.6% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The sarcopenia treatment market has been segmented on the basis of treatment type and distribution channel. The market, by treatment type, is segmented into vitamin D and calcium supplements, protein supplements, vitamin B12 supplements, and others. The sarcopenia treatment market, based on distribution channel, is segmented into pharmacies, retail channels, online channels, and others. The market, based on geography, is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, Rest of South & Central America).
Segmental Analysis:
The sarcopenia treatment market, by treatment type, is segmented into vitamin D and calcium supplements, protein supplements, vitamin B12 supplements, and others. The vitamin D and calcium supplements segment held the largest share of the market in 2022. The sarcopenia treatment market for this segment is anticipated to record the highest CAGR of 6.5% during 2022–2030. Being a fat-soluble vitamin, vitamin D is crucial for maintaining calcium homeostasis and healthy bone metabolism. The supplementation of vitamin D has been studied as a useful dietary strategy to reduce the risk of sarcopenia. Older adults with suboptimal vitamin D levels are highly susceptible to sarcopenia, often associated with falls, hospitalization, and other adverse effects.
The sarcopenia treatment market, by distribution channel, is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held a substantial market share in 2022. However, the online channels segment is predicted to register the fastest CAGR of 6.4% during 2022–2030. Supplements are available at pharmacies as over-the-counter medicines. Many OTC products composed of various dietary supplements such as vitamin D, vitamin B12, and protein supplements are available on the market, which are prescribed as a part of the sarcopenia treatment regime.
Cashless transaction is a major benefit associated with the progress of online retailers, which helps them expand their reach in non-metro cities. A few of the major online channels that sell supplements for sarcopenia treatment products are apollo pharmacy, HealthKart, and 1mg. The rising number of internet users, ease of access to several brands, fast-paced lifestyle, 24×7 availability of a wide range of products, and high accessibility of shopping platforms are the key factors driving the sales of sarcopenia supplements through the online channel.
Regional Analysis:
Based on geography, the global sarcopenia treatment market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the global sarcopenia treatment market. Asia Pacific is expected to register the highest CAGR during 2022–2030. The sarcopenia treatment market growth in North America is attributed to the rising popularity of nutraceutical supplements as a treatment option, the surging prevalence of orthopedic disorders, and the increasing cases of vitamin B12 and vitamin D deficiency in the geriatric population.
The sarcopenia treatment market in North America is further split into the US, Canada, and Mexico. Sarcopenia prevalence varies with age and gender; elderly people residing in assisted living facilities or communities in the US are at a higher risk of developing this condition. According to the National Institute of Health, the anticipated hospitalization cost for persons with sarcopenia in the US was US$ 40.4 billion in 2019. On average, people suffering from this condition pay US$ 2,315 more for hospital visits every year than people with normal muscle mass and function; they are almost twice as likely to be hospitalized than people without sarcopenia. Studies suggest that at least 10% reduction in the loss of skeletal muscle strength can prevent sarcopenia and save ~US$ 1 billion in annual US medical care expenses.
Canada is one of the fastest-growing markets for sarcopenia treatments. The market growth in this country is evident with a vast number of orthopedic disorder cases reported every year, mainly due to vitamin and nutrition deficiencies. According to statistics by the Public Health Agency of Canada (PHAC), over 2.3 million people in Canada are reported to have osteoporosis. Sarcopenia is one of the important causes of osteoporosis. Osteoporosis is a major risk factor that causes over 80% of all fractures in people aged 50 and above. Vitamins, calcium, and proteins play an important role in preventing and treating sarcopenia. Ongoing studies on the benefits of supplements on bone health along with advancements in nutraceuticals are expected to generate significant demand for sarcopenia treatments in Canada in the coming years.
Industry Developments and Future Opportunities:
A few major players operating in the sarcopenia treatment market are increasingly focusing on drug development to treat sarcopenia. Novel sarcopenia treatments are currently being developed and tested in clinical trials. A few of these products are mentioned below:
Sarcopenia Drug Under Clinical Development
Company Name | Interventions | Conditions | Clinical Trial Stage |
Abbott Nutrition | Medical Food with AN777 Oral Nutritional Formula | Malnutrition Sarcopenia | PHASE3 |
Nutricia Research | Dietary Supplement: Bolus ONS A Dietary Supplement: Bolus ONS B Dietary Supplement: Bolus ONS C Dietary Supplement: Bolus ONS D | Sarcopenia | PHASE1 |
Novartis Pharmaceuticals | Drug: Bimagrumab | Sarcopenia | PHASE2 |
McMaster University | Behavioral: Step Reduction | Sarcopenia | PHASE1 |
Metabolic Technologies Inc. | Dietary Supplement: Placebo Drug: HMB Plus Vitamin D Behavioral: Non-Exercise Behavioral: Exercise | Sarcopenia | PHASE1 |
Merck Sharp & Dohme LLC | Drug: Comparator MK-077 Drug: Comparator Placebo | Sarcopenia | PHASE2 |
Immunotec Inc. | Dietary Supplement: Immunocal Dietary Supplement: Casein | Aging|Sarcopenia | PHASE2 |
Lijun Yang | Combination Product: 3-Month Intensive Intervention | Sarcopenia | PHASE4 |
Regeneron Pharmaceuticals | Drug: REGN1033 (SAR391786) Drug: Placebo | Sarcopenia | PHASE2 |
Source: Company Websites and The Insight Partners Analysis
Therefore, the extending pipeline of drugs that are in different stages of clinical development presents significant opportunities for the sarcopenia treatment market growth.
Sarcopenia Treatment Market Report Scope
Competitive Landscape and Key Companies:
Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc., Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC are among the prominent companies in the sarcopenia treatment market. These companies focus on introducing new technologies, upgrading existing products, and expanding geographic reach to meet the growing consumer demand worldwide.
- In October 2023, Metagenics LLC completed the acquisition of 100% shares of Amipro Advanced Development Products. For many years, Ampiro has been the exclusive distributor of Metagenics LLC’s products in South Africa. The acquisition has strengthened the company’s distribution network in the country, further allowing it to have direct distribution operations in all major EMEA countries.
- In September 2023, Biophytis received Food and Drug Administration (FDA) authorization to launch its SARA-31 study in the US. It is the first-ever phase 3 study in the sarcopenia treatment specialty.
- In September 2022, Abbott India Ltd, a subsidiary of Abbott Laboratories, launched Ensure with HMB, a new formulation. The Ensure with HMB was launched to provide dietary support to elderly population in Indian. The product is formulated with the special and exclusive ingredient β-hydroxy-β-methyl butyrate (HMB), which helps counteract muscle loss, and restore strength and energy.
- In March 2022, MusclePharm Corporation, a global provider of leading sports nutrition and lifestyle brands of nutritional supplements, expanded its portfolio with the addition of the ready-to-drink protein category as it launched its new whey protein drink.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Treatment Type, Distribution Channel, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The progressive loss of muscular mass, strength, and function is known as sarcopenia. The illness, which is most common in the elderly, is said to be brought on by ageing. Sarcopenia can significantly lower the quality of life by making it harder to carry out daily activities. It may result in the need for long-term care.
Sarcopenia has an impact on the musculoskeletal system and is a significant contributor to fractures, falls, and an increase in frailty. Hospital stays and surgical procedures brought on by these illnesses raise the possibility of complications, including death. Hormone supplements can be used to build muscle and treat sarcopenia. However, there aren't any FDA-approved drugs available right now to treat sarcopenia.
The factors that are driving growth of the market are upsurge in geriatric population and rise in malnutrition and vitamin deficiency among adults.
The sarcopenia treatment market majorly consists of the players such as Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc., Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC among others.
US holds the largest market share in sarcopenia treatment market. Sarcopenia prevalence varies with age and gender; elderly people residing in assisted living facilities or communities in the US are at a higher risk of developing this condition. According to the National Institute of Health, in 2019, the anticipated hospitalization cost for persons with sarcopenia in the US was US$ 40.4 billion. People with sarcopenia pay US$ 2,315 more for hospital visits than people with normal muscle mass and function every year on average; they are almost twice as likely to be hospitalized than people without sarcopenia.
Asia Pacific is expected to be the fastest growing region in the sarcopenia treatment market. Asia is the world’s most populated continent with a rapidly aging population, and sarcopenia-related issues are becoming more prevalent in several Asian countries. Asians lead extremely different lifestyles and follow different dietary habits than people from the Western world. In Asia, sarcopenia in older individuals is more common in males (prevalence 9.6–22.1%) than females (prevalence 7.7–21.8%). Asian Working Group for Sarcopenia (AWGS) aims to promote sarcopenia research.
The sarcopenia treatment market, based on distribution channel, is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held a substantial market share in 2022. However, the online channels segment is predicted to register the fastest CAGR during 2022–2030.
The sarcopenia treatment market, based on treatment type, is segmented into vitamin D and calcium supplements, protein supplements, vitamin B12 supplements, and others. The vitamin D and calcium supplements segment held the largest share of the market in 2022.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Sarcopenia Treatment Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Sarcopenia Treatment Market – Key Industry Dynamics
5.1 Sarcopenia Treatment Market – Key Industry Dynamics
5.2 Market Drivers
5.2.1 Upsurge in Geriatric Population
5.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
5.3 Key Market Restraints:
5.3.1 Unavailability of Direct Interventions
5.4 Key Market Opportunities:
5.4.1 Products in Clinical Trial Phases
5.5 Future Trends:
5.5.1 Rising Awareness About Sarcopenia
5.6 Impact of Drivers and Restraints:
6. Sarcopenia Treatment Market – Global Market Analysis
6.1 Sarcopenia Treatment Market Revenue (US$ Million), 2022 – 2030
6.2 Sarcopenia Treatment Market Forecast and Analysis
7. Sarcopenia Treatment Market Analysis – By Treatment Type
7.1 Vitamin D and Calcium Supplement
7.1.1 Overview
7.1.2 Vitamin D and Calcium Supplement Market, Revenue and Forecast to 2030 (US$ Million)
7.2 Protein Supplement
7.2.1 Overview
7.2.2 Protein Supplement Market, Revenue and Forecast to 2030 (US$ Million)
7.3 Vitamin B12 Supplement
7.3.1 Overview
7.3.2 Vitamin B12 Supplement Market, Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others Market, Revenue and Forecast to 2030 (US$ Million)
8. Sarcopenia Treatment Market Analysis – By Distribution Channel
8.1 Pharmacies
8.1.1 Overview
8.1.2 Pharmacies Market, Revenue and Forecast to 2030 (US$ Million)
8.2 Retail Channels
8.2.1 Overview
8.2.2 Retail Channels Market, Revenue and Forecast to 2030 (US$ Million)
8.3 Online Channels
8.3.1 Overview
8.3.2 Online Channels Market, Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others Market, Revenue and Forecast to 2030 (US$ Million)
9. Sarcopenia Treatment Market – Geographical Analysis
9.1 Overview
9.2 North America
9.2.1 North America Sarcopenia Treatment Market Overview
9.2.2 North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.2.3 North America Sarcopenia Treatment Market Breakdown by Treatment Type
9.2.3.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Treatment Type
9.2.4 North America Sarcopenia Treatment Market Breakdown by Distribution Channel
9.2.4.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Distribution Channel
9.2.5 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Country
9.2.5.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Country
9.2.5.2 United States Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.2.5.2.1 United States Sarcopenia Treatment Market Breakdown by Treatment Type
9.2.5.2.2 United States Sarcopenia Treatment Market Breakdown by Distribution Channel
9.2.5.3 Canada Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.2.5.3.1 Canada Sarcopenia Treatment Market Breakdown by Treatment Type
9.2.5.3.2 Canada Sarcopenia Treatment Market Breakdown by Distribution Channel
9.2.5.4 Mexico Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.2.5.4.1 Mexico Sarcopenia Treatment Market Breakdown by Treatment Type
9.2.5.4.2 Mexico Sarcopenia Treatment Market Breakdown by Distribution Channel
9.3 Europe
9.3.1 Europe Sarcopenia Treatment Market Overview
9.3.2 Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.3.3 Europe Sarcopenia Treatment Market Breakdown by Treatment Type
9.3.3.1 Europe Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Treatment Type
9.3.4 Europe Sarcopenia Treatment Market Breakdown by Distribution Channel
9.3.4.1 Europe Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Distribution Channel
9.3.5 Europe Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Country
9.3.5.1 Europe Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Country
9.3.5.2 Germany Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.3.5.2.1 Germany Sarcopenia Treatment Market Breakdown by Treatment Type
9.3.5.2.2 Germany Sarcopenia Treatment Market Breakdown by Distribution Channel
9.3.5.3 France Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.3.5.3.1 France Sarcopenia Treatment Market Breakdown by Treatment Type
9.3.5.3.2 France Sarcopenia Treatment Market Breakdown by Distribution Channel
9.3.5.4 United Kingdom Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.3.5.4.1 United Kingdom Sarcopenia Treatment Market Breakdown by Treatment Type
9.3.5.4.2 United Kingdom Sarcopenia Treatment Market Breakdown by Distribution Channel
9.3.5.5 Italy Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.3.5.5.1 Italy Sarcopenia Treatment Market Breakdown by Treatment Type
9.3.5.5.2 Italy Sarcopenia Treatment Market Breakdown by Distribution Channel
9.3.5.6 Spain Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.3.5.6.1 Spain Sarcopenia Treatment Market Breakdown by Treatment Type
9.3.5.6.2 Spain Sarcopenia Treatment Market Breakdown by Distribution Channel
9.3.5.7 Rest of Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.3.5.7.1 Rest of Europe Sarcopenia Treatment Market Breakdown by Treatment Type
9.3.5.7.2 Rest of Europe Sarcopenia Treatment Market Breakdown by Distribution Channel
9.4 Asia Pacific
9.4.1 Asia Pacific Sarcopenia Treatment Market Overview
9.4.2 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.4.3 Asia Pacific Sarcopenia Treatment Market Breakdown by Treatment Type
9.4.3.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Treatment Type
9.4.4 Asia Pacific Sarcopenia Treatment Market Breakdown by Distribution Channel
9.4.4.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Distribution Channel
9.4.5 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Country
9.4.5.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Country
9.4.5.2 China Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.4.5.2.1 China Sarcopenia Treatment Market Breakdown by Treatment Type
9.4.5.2.2 China Sarcopenia Treatment Market Breakdown by Distribution Channel
9.4.5.3 India Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.4.5.3.1 India Sarcopenia Treatment Market Breakdown by Treatment Type
9.4.5.3.2 India Sarcopenia Treatment Market Breakdown by Distribution Channel
9.4.5.4 Japan Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.4.5.4.1 Japan Sarcopenia Treatment Market Breakdown by Treatment Type
9.4.5.4.2 Japan Sarcopenia Treatment Market Breakdown by Distribution Channel
9.4.5.5 South Korea Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.4.5.5.1 South Korea Sarcopenia Treatment Market Breakdown by Treatment Type
9.4.5.5.2 South Korea Sarcopenia Treatment Market Breakdown by Distribution Channel
9.4.5.6 Australia Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.4.5.6.1 Australia Sarcopenia Treatment Market Breakdown by Treatment Type
9.4.5.6.2 Australia Sarcopenia Treatment Market Breakdown by Distribution Channel
9.4.5.7 Rest of APAC Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.4.5.7.1 Rest of APAC Sarcopenia Treatment Market Breakdown by Treatment Type
9.4.5.7.2 Rest of APAC Sarcopenia Treatment Market Breakdown by Distribution Channel
9.5 Middle East and Africa
9.5.1 Middle East and Africa Sarcopenia Treatment Market Overview
9.5.2 Middle East and Africa Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.5.3 Middle East and Africa Sarcopenia Treatment Market Breakdown by Treatment Type
9.5.3.1 Middle East and Africa Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Treatment Type
9.5.4 Middle East and Africa Sarcopenia Treatment Market Breakdown by Distribution Channel
9.5.4.1 Middle East and Africa Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Distribution Channel
9.5.5 Middle East and Africa Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Country
9.5.5.1 Middle East and Africa Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Country
9.5.5.2 South Africa Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.5.5.2.1 South Africa Sarcopenia Treatment Market Breakdown by Treatment Type
9.5.5.2.2 South Africa Sarcopenia Treatment Market Breakdown by Distribution Channel
9.5.5.3 Saudi Arabia Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.5.5.3.1 Saudi Arabia Sarcopenia Treatment Market Breakdown by Treatment Type
9.5.5.3.2 Saudi Arabia Sarcopenia Treatment Market Breakdown by Distribution Channel
9.5.5.4 United Arab Emirates Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.5.5.4.1 United Arab Emirates Sarcopenia Treatment Market Breakdown by Treatment Type
9.5.5.4.2 United Arab Emirates Sarcopenia Treatment Market Breakdown by Distribution Channel
9.5.5.5 Rest of Middle East and Africa Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.5.5.5.1 Rest of Middle East and Africa Sarcopenia Treatment Market Breakdown by Treatment Type
9.5.5.5.2 Rest of Middle East and Africa Sarcopenia Treatment Market Breakdown by Distribution Channel
9.6 South and Central America
9.6.1 South and Central America Sarcopenia Treatment Market Overview
9.6.2 South and Central America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.6.3 South and Central America Sarcopenia Treatment Market Breakdown by Treatment Type
9.6.3.1 South and Central America Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Treatment Type
9.6.4 South and Central America Sarcopenia Treatment Market Breakdown by Distribution Channel
9.6.4.1 South and Central America Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Distribution Channel
9.6.5 South and Central America Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Country
9.6.5.1 South and Central America Sarcopenia Treatment Market Revenue and Forecast and Analysis – By Country
9.6.5.2 Brazil Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.6.5.2.1 Brazil Sarcopenia Treatment Market Breakdown by Treatment Type
9.6.5.2.2 Brazil Sarcopenia Treatment Market Breakdown by Distribution Channel
9.6.5.3 Argentina Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.6.5.3.1 Argentina Sarcopenia Treatment Market Breakdown by Treatment Type
9.6.5.3.2 Argentina Sarcopenia Treatment Market Breakdown by Distribution Channel
9.6.5.4 Rest of South and Central America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
9.6.5.4.1 Rest of South and Central America Sarcopenia Treatment Market Breakdown by Treatment Type
9.6.5.4.2 Rest of South and Central America Sarcopenia Treatment Market Breakdown by Distribution Channel
10. Sarcopenia Treatment Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Sarcopenia Treatment Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Abbott Laboratories
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Bayer AG
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Metagenics LLC
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Nestle Health Science SA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Novartis AG
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Pfizer Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Sanofi SA
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Amway Corp
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 GSK Plc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Makers Nutrition LLC
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
List of Tables
Table 1. Sarcopenia Treatment Market Segmentation
Table 2. Sarcopenia Drug Under Clinical Development
Table 3. Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Million)
Table 4. Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Million) – By Treatment Type
Table 5. Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Million) – By Distribution Channel
Table 6. North America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 7. North America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 8. North America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Country
Table 9. United States Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 10. United States Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 11. Canada Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 12. Canada Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 13. Mexico Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 14. Mexico Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 15. Europe Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 16. Europe Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 17. Europe Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Country
Table 18. Germany Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 19. Germany Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 20. France Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 21. France Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 22. United Kingdom Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 23. United Kingdom Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 24. Italy Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 25. Italy Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 26. Spain Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 27. Spain Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 28. Rest of Europe Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 29. Rest of Europe Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 30. Asia Pacific Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 31. Asia Pacific Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 32. Asia Pacific Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Country
Table 33. China Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 34. China Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 35. India Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 36. India Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 37. Japan Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 38. Japan Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 39. South Korea Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 40. South Korea Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 41. Australia Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 42. Australia Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 43. Rest of APAC Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 44. Rest of APAC Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 45. Middle East and Africa Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 46. Middle East and Africa Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 47. Middle East and Africa Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Country
Table 48. South Africa Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 49. South Africa Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 50. Saudi Arabia Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 51. Saudi Arabia Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 52. United Arab Emirates Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 53. United Arab Emirates Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 54. Rest of Middle East and Africa Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 55. Rest of Middle East and Africa Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 56. South and Central America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 57. South and Central America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 58. South and Central America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Country
Table 59. Brazil Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 60. Brazil Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 61. Argentina Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 62. Argentina Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 63. Rest of South and Central America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Treatment Type
Table 64. Rest of South and Central America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn) – By Distribution Channel
Table 65. Recent Inorganic Growth Strategies in the Sarcopenia Treatment Market
Table 66. Recent Organic Growth Strategies in the Sarcopenia Treatment Market
Table 67. Glossary of Terms, Sarcopenia Treatment Market
List of Figures
Figure 1. Sarcopenia Treatment Market Segmentation, By Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Sarcopenia Treatment Market Breakdown by Geography, 2022 and 2030 (%)
Figure 5. Sarcopenia Treatment Market Revenue (US$ Million), 2022 – 2030
Figure 6. Sarcopenia Treatment Market Share (%) – By Treatment Type, 2022 and 2030
Figure 7. Vitamin D and Calcium Supplement Market Revenue and Forecasts To 2030 (US$ Million)
Figure 8. Protein Supplement Market Revenue and Forecasts To 2030 (US$ Million)
Figure 9. Vitamin B12 Supplement Market Revenue and Forecasts To 2030 (US$ Million)
Figure 10. Others Market Revenue and Forecasts To 2030 (US$ Million)
Figure 11. Sarcopenia Treatment Market Share (%) – By Distribution Channel, 2022 and 2030
Figure 12. Pharmacies Market Revenue and Forecasts To 2030 (US$ Million)
Figure 13. Retail Channels Market Revenue and Forecasts To 2030 (US$ Million)
Figure 14. Online Channels Market Revenue and Forecasts To 2030 (US$ Million)
Figure 15. Others Market Revenue and Forecasts To 2030 (US$ Million)
Figure 16. Sarcopenia Treatment Market Breakdown by Region, 2022 and 2030 (%)
Figure 17. North America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 18. North America Sarcopenia Treatment Market Breakdown by Treatment Type (2022 and 2030)
Figure 19. North America Sarcopenia Treatment Market Breakdown by Distribution Channel (2022 and 2030)
Figure 20. North America Sarcopenia Treatment Market Breakdown by Key Countries, 2022 and 2030 (%)
Figure 21. United States Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 22. Canada Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 23. Mexico Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 24. Europe Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 25. Europe Sarcopenia Treatment Market Breakdown by Treatment Type (2022 and 2030)
Figure 26. Europe Sarcopenia Treatment Market Breakdown by Distribution Channel (2022 and 2030)
Figure 27. Europe Sarcopenia Treatment Market Breakdown by Key Countries, 2022 and 2030 (%)
Figure 28. Germany Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 29. France Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 30. United Kingdom Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 31. Italy Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 32. Spain Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 33. Rest of Europe Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 34. Asia Pacific Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 35. Asia Pacific Sarcopenia Treatment Market Breakdown by Treatment Type (2022 and 2030)
Figure 36. Asia Pacific Sarcopenia Treatment Market Breakdown by Distribution Channel (2022 and 2030)
Figure 37. Asia Pacific Sarcopenia Treatment Market Breakdown by Key Countries, 2022 and 2030 (%)
Figure 38. China Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 39. India Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 40. Japan Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 41. South Korea Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 42. Australia Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 43. Rest of APAC Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 44. Middle East and Africa Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 45. Middle East and Africa Sarcopenia Treatment Market Breakdown by Treatment Type (2022 and 2030)
Figure 46. Middle East and Africa Sarcopenia Treatment Market Breakdown by Distribution Channel (2022 and 2030)
Figure 47. Middle East and Africa Sarcopenia Treatment Market Breakdown by Key Countries, 2022 and 2030 (%)
Figure 48. South Africa Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 49. Saudi Arabia Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 50. United Arab Emirates Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 51. Rest of Middle East and Africa Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 52. South and Central America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 53. South and Central America Sarcopenia Treatment Market Breakdown by Treatment Type (2022 and 2030)
Figure 54. South and Central America Sarcopenia Treatment Market Breakdown by Distribution Channel (2022 and 2030)
Figure 55. South and Central America Sarcopenia Treatment Market Breakdown by Key Countries, 2022 and 2030 (%)
Figure 56. Brazil Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 57. Argentina Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 58. Rest of South and Central America Sarcopenia Treatment Market – Revenue and Forecast to 2030(US$ Mn)
Figure 59. Growth Strategies in the Sarcopenia Treatment Market
The List of Companies - Sarcopenia Treatment Market
- Abbott Laboratories
- Bayer AG
- Metagenics LLC
- Nestle Health Science SA
- Novartis AG
- Pfizer Inc
- Sanofi SA
- Amway Corp
- GSK Plc
- Makers Nutrition LLC
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For